Point-of-Care Testing for Chlamydia and Gonorrhoea: Implications for Clinical Practice

Lisa Natoli1,2*, Lisa Maher1, Mark Shephard3, Belinda Hengel3, Annie Tangey4, Steven G. Badman1, James Ward6, Rebecca J. Guy1 and on behalf of the TTANGO Investigators

1 The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia, 2 The Burnet Institute, Melbourne, Victoria, Australia, 3 Apunipima Cape York Health Council, Cairns, Queensland, Australia, 4 Nganinyjarra Health Service, Alice Springs, Northern Territory, Australia, 5 Flinders University International Centre for Point of-Care Testing, Flinders University, Adelaide, South Australia, Australia, 6 Baker IDI, Alice Springs, Northern Territory, Australia

Abstract

Objectives: Point-of-care (POC) testing for chlamydia (CT) and gonorrhoea (NG) offers a new approach to the diagnosis and management of these sexually transmitted infections (STIs) in remote Australian communities and other similar settings. Diagnosis of STIs in remote communities is typically symptom driven, and for those who are asymptomatic, treatment is generally delayed until specimens can be transported to the reference laboratory, results returned and the patient recalled. The objective of this study was to explore the clinical implications of using CT/NG POC tests in routine clinical care in remote settings.

Methods: In-depth qualitative interviews were conducted with a purposively selected group of 18 key informants with a range of sexual health and laboratory expertise.

Results: Participants highlighted the potential impact POC testing would have on different stages of the current STI management pathway in remote Aboriginal communities and how the pathway would change. They identified implications for offering a POC test, specimen collection, conducting the POC test, syndromic management of STIs, pelvic inflammatory disease diagnosis and management, interpretation and delivery of POC results, provision of treatment, contact tracing, management of client flow and wait time, and re-testing at 3 months after infection.

Conclusions: The introduction of POC testing to improve STI service delivery requires careful consideration of both its advantages and limitations. The findings of this study will inform protocols for the implementation of CT/NG POC testing, and also STI testing and management guidelines.

Introduction

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) cause sexually transmissible infections (STIs) that are fully curable with single dose treatment but are often asymptomatic for long periods of time [1]. Both infections can lead to serious complications [1] including pelvic inflammatory disease (PID) [2], ectopic pregnancy and tubal factor infertility [3,4], and a range of adverse pregnancy and neonatal outcomes.[5,6]

To interrupt infection transmission in populations at higher risk of CT and NG infection, and reduce the risk of sequelae, it is important to diagnose and provide treatment as early as possible in people with these infections [7]. A number of studies have found that with just a few weeks delay between testing and treatment, 2–3% of patients with CT infection have already developed PID [8,9]. Timely diagnosis also enables contacts to be identified and treated through partner notification strategies.

In many clinical settings in remote areas of the world, distance from laboratories means there are significant delays in accessing diagnostics [10,11], and in many resource poor countries, laboratory infrastructure is either not available or limited [12]. In the absence of diagnostic tests for STIs, the World Health Organisation recommends ‘syndromic management’ as the approach to diagnosing and treating common STIs [13]. This approach involves immediate treatment for STIs based on an approach to diagnosing and treating common STIs [13]. This approach involves immediate treatment for STIs based on a range of symptoms and signs [14–16]. In remote parts of Australia, clinical services are located many hundreds, even thousands of kilometres, away from the laboratory, specimen transport may only occur once a week [17] and thus results may not be received from laboratories for 7–10 days. Typically, remote...
clinical services undertake syndromic management plus send specimens to laboratories for testing, with asymptomatic patients treated once the results are received from the laboratory.

However, syndromic management leaves many infections untreated as well as causing overtreatment in others [18,19]. Over 80% of CT infections and 80% of NG infections in females and 50% in males are asymptomatic [20–22]. Thus only a small proportion of people with CT or NG present to clinical services with the symptoms that are required to [23] qualify for immediate treatment using the syndromic approach [14–16]. Furthermore, symptom-driven diagnosis has poor sensitivity and specificity for detecting infections, particularly in women. It is also difficult to develop algorithms with good sensitivity and specificity that are applicable in a range of primary care settings and across geographic locations [19,24].

Point-of-care (POC) testing has the potential to improve diagnosis and management of STIs in areas with no or limited access to pathology services or in remote areas where there are considerable delays in receiving laboratory results. To date, use of CT and NG POC tests has been limited due to deficiencies of the available technology. For example, the only devices which have been commercially available have involved lateral flow and immuno-chromatographic detection and have exhibited poor sensitivity and specificity, most detect single infections only, and many are complicated to use [25,26]. Recently, a molecular-based POC test system for the dual detection of CT and NG was developed [12]. The Xpert CT/NG assay (Cepheid) has very high sensitivity and specificity for these two tests, is easy to use, and results are available in 90 minutes. The CT/NG test was approved by regulatory bodies in the US, Europe and Australia in 2013. Other molecular based POC tests are under development [12].

This new generation of molecular POC tests provide an opportunity to expand the use of POC testing. However to our knowledge, no studies have examined the clinical implications of introducing CT/NG POC tests. In the context of the ‘Test Treat ANel GO’ (TTANGO) Trial [27], a randomised controlled trial of the GeneXpert in remote communities of Australia, we used qualitative methods to explore for the first time, the clinical implications of using CT/NG POC tests in routine clinical care.

Methods and Materials

Ethics statement

Ethical approval for the study was received from the West Australian Aboriginal Health Information and Ethics Committee, the West Australian Community Health Board Research Ethics Committee, the Townsville and Cairns Health Service District Human Research Ethics Committees and, the Aboriginal Health Research Ethics Committee of South Australia.

Setting

Australia has extensive and high quality laboratory infrastructure, like other resource-rich settings, with numerous laboratories all using highly accurate PCR tests. STI testing is available at primary care centres, sexual health clinics and family planning clinics and other settings, with primary care diagnosing most STIs in Australia. STI testing is recommended for: (i) patients with symptoms or considered high risk, (ii) annually in young people and men who have sex with men (MSM), and (iii) 3–6 monthly in higher risk MSM. A repeat test at 3 months is also recommended to detect re-infections in any person diagnosed with an STI [20–30]. POC testing by PCR for STIs is not yet established in Australia.

In urban areas clinical services are staffed by doctors and nurses, and clinics can send a specimen to a laboratory and generally receive a result within a few days, with treatment occurring soon after. Specialist sexual health services also have access to POC microscopy for symptomatic patients.

In remote Australian Aboriginal communities, there are only generalist primary health care centres, which are staffed by nurses and Aboriginal Health Practitioners mainly, with most having ‘fly in’ and ‘fly out’ Medical Officer support. Client mobility is typically high, and follow-up systems are not always effective, with 11–25% of people not treated for STIs in some areas, and the average time to treatment estimated to be 21 days for asymptomatic patients [31]. In remote Australian Aboriginal communities the prevalence of CT among 16–34 year olds was estimated to be 9% for CT and 7% for NG in 2010, and was highest in 16–19 year olds. This compares with 3–4% for CT in non-Indigenous youth aged 16–29 years and <1% for NG, making timely treatment even more important [32–34].

The current STI management pathway common in remote primary care health services is reflected in the top half of Figure 1. Standard processes for ordering STI tests and dispensing treatment vary according to jurisdiction, the professional qualification of health care workers and health service guidelines. For example, in some very remote services, Registered Nurses are able to administer STI treatments presumptively or on basis of a test result according to standard protocols, and without a doctor’s order. Also Nurse Practitioners may be accredited to assess patients for STIs, order pertinent tests and provide presumptive treatment according to clinical practice guidelines. In addition, standing orders allowing antibiotic treatment are often in place to compensate for the absence of medical staff where necessary.

Study design

Between March and August 2013, in-depth qualitative interviews were conducted with key experts to explore, among other issues, the likely impact of CT/NG POC testing on current clinical practice. The focus was on POC testing generally and not limited to molecular type tests, although molecular tests were often the focus of discussion.

Participants

Purposive sampling was used to identify participants with relevant sexual health and/or laboratory expertise. We sought to interview male and female participants with remote and urban expertise, broadly representative of the eight Australian states and territories.

Interviews

Interviews were conducted by LN via telephone, skype or, where possible, in person, and took between 30 and 75 minutes. Written informed consent was obtained from all participants.

Data management and analysis

Recruitment continued until the data were saturated or no new themes emerged [35]. Interviews were digitally-recorded, transcribed verbatim and transcripts were later checked for accuracy against the recordings and to ensure familiarisation prior to analysis. Transcripts were uploaded into QSR Nvivo (Version 10), a qualitative data management and analysis program (QRS International PTY Ltd, Melbourne, Australia). Each transcript was systematically coded and content analysis was performed to examine frequencies of recurring codes and to allocate salient themes [36].
Results

Participants (n = 18) had sexual health and/or laboratory expertise and included sexual health physicians and nurses in urban, regional and remote health services (n = 8), academics (n = 2), policy makers (n = 4), and laboratory based microbiologists (n = 4). The majority of participants were male (56%) with the average age being 49 years (range 39–58 years). Participants were drawn from five of the eight Australian States and Territories. Nine of the participants were urban based, six worked across both urban and remote settings and three worked predominantly in remote communities.

Participants highlighted the potential impact POC testing would have on different stages of the current STI management pathway in remote Aboriginal communities (upper half of Figure 1) and how the pathway would change (lower half of Figure 1). The results are summarised according to different thematic components of the STI management pathway.

Offering a POC test

Several participants highlighted there may be some novelty attached to POC testing and staff may need to be prepared in order to manage expectations for testing from patients who may be curious about POC testing but not necessarily at risk for STIs.

[You could have] anyone coming in and going “I want that test” when actually they don’t fit, they’re not at risk and it’s just a curiosity and the clinic staff have to manage that and they have to know how to manage that (Participant #15).

Some suggested that staff may have a lower threshold for testing, or be more inclined to offer testing without justification, purely because of the convenience of having the test on site.

Others expressed particular concerns about testing in children/adolescents.

[S]ometimes they [staff new to remote settings] do tests when it’s inappropriate … I just think there has been concern about doing … STI screens in kids, looking at things - well if it’s negative they haven’t been sexually abused that type of thing, so you just need to make sure that that tendency doesn’t increase (Participant #13).

Participants noted the importance of appropriately targeted testing to ensure efficient use of scarce resources. This consideration is already pertinent under current practice, as one participant noted.

Adult health checks [an Australian government initiative that targets Aboriginal people (15–54 yrs) to facilitate early detection, diagnosis and management of common, treatable conditions] have been a huge facilitator to increasing the uptake of STI testing in general but … when you look at a lot of those remote communities more than a third of the testing is being done in people over the age of 40 (Participant #15).

Participants highlighted the need for clear protocols to guide appropriate POC testing of both index cases and contacts.
POCT for Chlamydia and Gonorrhoea: Implications for Clinical Practice

Specimen collection

Depending on current practice within the service, participants noted that consideration would need to be given to the timing of specimen collection, and whether this happens before or after the clinical consultation. A number of participants felt that specimen collection could be integrated into processes where urine would usually be collected.

"[I]t could be simply “oh you're here for a health check-up, before we start the health check-up can we have a urine sample?” and then while you’re doing the health check the test is being processed (Participant #4)."

Some participants felt that practitioners would also need to understand POC test characteristics and limitations (given that sensitivity and specificity may differ from routine laboratory tests), depending on the purpose of testing.

"I find that practitioners in general have very low levels of knowledge around screening, but when you actually talk to them … they’re all screening for something and they’re not thinking about that as a screening test and they’re not thinking about the difference between what you test and what information goes with it and how much time you spend doing it in a context of screening, as opposed to in a context of doing a diagnostic test (Participant #15)."

Some participants felt that for the full benefits of POC testing to be attained (such as extending the reach of testing via non-medical staff in remote services), consideration may need to be given to which health service staff have authority to initiate testing. Potentially there are implications for clinical guidelines and legislative change, as in some Australian jurisdictions pathology request forms can only be signed by a medical practitioner. In the context of POC testing, it was felt that the process for authorisation of testing needs to be more ‘rapid’.

"[A]ll health workers that I’ve come across are in principle able to … collect the specimen; it’s the doctors that request the tests, so again you might need to have some sort of review of who is requesting the test. I don’t think it needs to be a doctor … in some places … doctors have refused to sign pathology forms when the nurses and health workers are perfectly capable of screening people … I think that probably ties into the legislation for the health workers and nurses about what they are able to do (Participant #15)."

Some participants suggested that the availability of POC testing might help to raise the profile of STIs and increase testing rates in health services where sexual health is not a high priority.

"So in a place where … screening isn’t happening consistently then I think it would be … great value … particularly in remote settings … I think a test like that would actually increase their [nurses] confidence around some management issues … increase their interest if you like (Participant #15)."

Syndromic management for STIs

Some participants suggested that symptomatic patients should continue to be treated in accordance with syndromic management protocols.

"[I]f someone is symptomatic should they or should they not have a POC test? Should they just have an ordinary PCR and also have a broader battery of tests. But particularly for remote Aboriginal communities in WA [Western Australia], not to approach that person from a syndromic paradigm would probably be unethical really (Participant #3)."

Alternatively, others suggested that syndromic management may become less applicable, as POC testing would help guide management and result in more targeted prescribing.

"[I]t does allow you to move from a syndromic approach, which is basically treating someone just because they’re a contact or because they’ve got symptoms, to treating them based on whether they have been diagnosed formally … or not (Participant #17)."

There was an understanding among participants that current treatment algorithms may need to alter slightly. For example, in relation to management of vaginal discharge, a negative chlamydia or NG result would need to direct clinicians to treat for other likely infections such as candida, trichomoniasis and bacterial vaginosis.

"Look, it’ll probably change those algorithms a bit, what will go in there is test for these things, if these things are negative then do this, I suppose. Which is treatment for BV [bacterial vaginosis] and trich [trichomoniasis] and anything else that may cause it (Participant #10)."
Treatment algorithms for urethral discharge in men may also need to change. However, as diagnosis and treatment of urethritis in men is generally well managed, one participant wondered whether this might be undermined by POC testing. For example urethritis can be caused by *Mycoplasma genitalium* which is not tested for but often treated inadvertently due to the antibiotics given syndromically for CT/NG.

If anything I think your risk in men with urethritis is under treatment, because at the moment they’re treating everyone pretty much on spec and before they get a test result, so … if people were going to start using it [a POC test] and then use it as a reason not to treat, that could be a potential risk for men (Participant #15).

In some jurisdictions, treatment guidelines recommend dual therapy (for both CT and NG) in cases of urethral discharge. However one participant queried whether treatment for both CT and NG should be given in the case of a CT only positive POC result. Some participants noted that the local epidemiology would be an important consideration in this instance.

If someone in a remote location had urethral discharge- I’m not familiar with the current version of the CARPA manual [guidelines for clinical practice used in many remote Australian communities] for example, but I expect they’re offering treatment for gonorrhoea and chlamydia together … [so] if you do a point-of-care test and it shows they’ve got chlamydia, not gonorrhoea, would you still treat them for gonorrhoea? So would that change that? (Participant # 9)

**PID diagnosis and management**

There was a suggestion that PID is generally underdiagnosed in remote settings and that POC testing might heighten awareness of health professionals and strengthen management of these cases.

I think it would reinforce management (referring to PID) in people’s head as well, when you’ve got something immediate, you know, if it’s a week down the track then people … might forget the details of that case, but if you’ve got it there immediately and you thought “oh yeah okay that’s what it is” (Participant #15).

At the same time, the potential to rely too heavily on a POC test was highlighted by some participants, particularly in relation to the differential diagnosis of pelvic pain.

You’re not just talking about chlamydia and gonorrhoea, you are actually talking about what the test means in the context of who and what presenting symptoms they’ve had … it’s not just here’s your test and it’s about the test, it’s actually about your predictive value of using that test depending on who you are testing … and getting across that understanding of how you interpret it … related to the individual that they’re testing basically or the age group if you like (Participant #15).

Some participants also questioned whether PID treatment algorithms would change in the context of a POC test.

But in terms of, for example, the PID treatment, if you did a swab on a woman with pelvic pain and did a point-of-care test that showed they had Chlamydia, I think that you’d be treating for PID, which covers Gonorrhoea treatment (Participant # 9).

**Interpretation and delivery of POC results**

Participants identified counselling and provision of test results to patients as a key area of practice that would be potentially impacted by POC testing, with the process being condensed into a much shorter timeframe than usual.

People may feel … a bit challenged by that, and that thought of not being able to … process that information or have time to think about it may actually be a bit of a concern. It … certainly adds a layer of complexity for the health care provider to explain … what the ins and outs of the test are, what the possibility of the false negatives, the false positives, what the treatment options are (Participant #7).

Participants noted that providing results on the same day as testing could result in the capacity to free up appointments and reduce the resourcing and effort that goes into client follow up.

For a service such as ours, obviously … you’re freeing up appointments … for other people if we can manage in a single consultation that diagnosis and management (Participant # 7).

Well, communicating results to patients- … If you can do it on the same day … there’s less work to be done in either ringing people, chasing people, bringing people back for review, that kind of thing. It wouldn’t eliminate it, but it would reduce that work quite substantially (Participant # 6).

During routine STI testing it is accepted best practice that clinicians should conduct a full STI screen involving HIV and syphilis in the context of a positive CT or NG result. One participant identified that POC testing may provide an opportunity for increased patient engagement and that this might open the door for a more comprehensive approach.

When you do their sexual history potentially they are under-reporting self-report stuff and then when there is a positive result it does provide an opportunity to have a more frank discussion about what else is going on in people’s lives. And then the opportunity to test for other … STIs like HIV that you otherwise would not have done (Participant #11).

**Provision of treatment**

While immediacy of treatment was recognised by many to be a fundamental benefit of POC testing, some participants felt that a review of policy or legislation may be necessary in some jurisdictions in order to facilitate timely dispensing of medication by non-medical staff.

I think we have standing orders for instance for nurses to be able to give Azithromycin in very defined circumstances so they can supply the medication that’s … prescribed to the doctor. But I think we need to look nationally at how we can facilitate that supply of medication by healthcare professionals other than doctors. So – because otherwise … it defeats the point … (Participant # 7).

In addition to informing clinicians about notifiable infections, it was noted that some laboratory service providers guide clinicians in treatment options, via comments provided on laboratory test results. In the absence of laboratory testing this guidance would no longer be available, and health professionals would need to have a heightened working knowledge of treatment guidelines.
Contact tracing

Participants identified contact tracing as a key area of practice that would be impacted by POC testing. Patients will need to be prepared for the possibility of discussing sexual contacts and possibly having them notified in a much shorter time frame.

Management of client flow and wait time

The ease of performing the POC test, the turnaround time for the test result and how simply POC testing could be integrated into routine workflow were important considerations for many participants, though it was recognised that this would be largely influenced by the type of test. In particular, participants highlighted how clinical workflow can be impacted by a positive test.

An important consideration highlighted by one participant is how critical it is for the test result to be read at a specific time point.

In particular, taking the opportunity to raise awareness about STI prevention in the context of a negative test result was highlighted.

Re-testing at 3 months after infection

In the context of non-medical or less experienced staff (eg. fly-in nurses) having greater ability to initiate STI testing, many participants emphasised the need for clear protocols to provide guidance about appropriate re-testing timeframes.

Discussion

Our study has identified that the introduction of POC testing to improve STI service delivery requires considerable forethought and planning [37,38]. While stakeholders identified a range of potential benefits of using this technology, they also highlighted that the integration of CT/NG POC testing to remote clinical practice needs careful consideration. Potentially it will result in some changes to the STI management pathway, and policy and clinical guidelines may need to be altered in response.

Participants identified a range of benefits of using POC testing in remote settings including more timely and targeted prescribing, particularly in the context of increasing NG resistance [39], freeing up staff time usually spent on follow-up of cases who haven’t returned for treatment, greater opportunities to offer a full STI screen for people with a positive test, more timely and targeted contact tracing, and more timely information to guide PID diagnosis and management. More targeted treatment is a common benefit raised in regards to POC testing, but other benefits were quite specific to CT and NG testing and management. The TTANGO trial aims to determine if these benefits will be realised.

A number of potential challenges were also raised. Many of these could be overcome by appropriate POC resources, training and support relating to the communication of results, logistics of testing and location of the POC device, and planned flow of patients through the clinic from the time of initial assessment through to treatment uptake (where indicated). However other issues raised will need careful discussion and planning. The potential to conduct “opportunistic” POC testing, in populations that would not otherwise be tested raises the importance of ensuring there are systems in place to ensure testing is only conducted by trained operators in response to a formal test request and systems are in place to address how to manage a positive
result. Also legislative changes may be needed if Aboriginal health practitioners are to conduct most STI testing and there is a preference for them to be able to request tests and provide treatment. As Aboriginal health practitioners are often the main care providers in remote services, the need for them to have greater authority in relation to initiating tests and providing treatment (according to guidelines) similarly applies to other areas of chronic disease and preventative health.

As the POCT assay being used in TTANGO (Xpert CT/NG) has sensitivity and specificity equivalent to the routine laboratory tests [40,41], treatment algorithms may need revision. For example, in the case of CT-only diagnoses, there would need to be clarity around treatment and whether, depending on local epidemiology, treatment for NG should also be provided (as per some current guidelines). This is an important consideration in the context of increasing antibiotic resistance by NG [39]. Also changes to syndromic management guidelines might be needed, but there would need to be careful consideration of whether syndromic management is completely stopped or altered. POCT test performance characteristics and local disease epidemiology would be important considerations. For example, syndromic management of vaginal discharge is poorly predictive of CT or NG infection, and a highly sensitive and specific molecular POCT test might facilitate more targeted treatment in this instance. If CT and NG are effectively excluded by a POCT test, then metronidazole plus an anti-candida cream should cover the remaining likely causes; specifically bacterial vaginosis, trichomonas, and candida. However, over-riding syndromic management of urethral discharge in men may be less straightforward. As several participants in the study noted, other organisms (such as M genitalium) are implicated in non-gonococcal urethritis [42], so treatment of symptomatic men will probably still be required, though an anti-gonococcal drug may no longer be necessary. Similarly for contact tracing, where usually contacts are treated presumptively, guidelines may need to be reviewed.

Our study has several limitations. The qualitative approach, small sample size and the non-random nature of the sampling strategy limit the generalisability of our findings. However, to overcome this, we purposively sampled a broad range of recognised experts from different disciplines and jurisdictions with expertise in the testing and diagnosis of STIs. Participant responses were influenced by participant expertise and familiarity with specific work environments, and may not reflect the real-life/on-ground situation in all health services. If POCT testing is introduced in the future, an assessment would need to be made in each health service setting, to determine the necessary changes to clinical practice and guidelines to incorporate POCT testing into practice and health service guidelines and protocols. Although the interviews focussed on remote Australian Aboriginal communities, the findings have relevance for STI clinical practice generally.

In conclusion, the findings of this qualitative research will inform guidelines related to implementation of CT/NG POCT testing, similar to those already available for HIV, syphilis and malaria POCT testing [43] [44] but tailored to specific issues related to CT/NG identified here. These findings will also guide policy makers should they wish to plan for POCT test implementation. Specifically, findings may inform: consideration of POCT test logistics in remote services (such as test location, power supply, refrigeration, and internet connectivity); the need to review existing legislative processes to facilitate timely generation of pathology requests by non-medical staff; revision of syndromic management algorithms; and, training considerations relevant to the integration of STI POCT testing in remote clinical practice.

Acknowledgments
The authors would like to acknowledge and thank the interview participants who gave so generously of their time. Test, Treat and Go (TTANGO) Investigators include Rebecca Guy, John Kaldor, Basil Donovan, David Wilson, Handan Wand, David Regan, Steven Badman and Louise Causer from the Kirby Institute, James Ward (Baker IDI), Belinda Hengel (Aparriina Health Council), Annie Tangey (Nganyatjarra Health Service), Lisa Natoili and David Anderson (Burnet Institute), David Whaley (The Queensland Pediatric Infectious Diseases Laboratory), Sepehr N. Tabrizi (The Royal Women's Hospital), Mark Shephard (Flinders University), and Christopher Fairley (University of Melbourne and Melbourne Sexual Health Centre). There are a number of collaborators critical to the trial’s success and these include: participating health services; Queensland Aboriginal and Islander Health Council; Queensland Health; Aboriginal Health Council of Western Australia; West Australia Department of Health; West Australian Country Health Service; Aboriginal Health Council of South Australia; South Australia Health; Western Diagnostic Pathology; PathWest; Pathology Queensland; National Reference Laboratory; and Cepheid. TTANGO is funded by a National Health and Medical Research Council (NHMRC) Project Grant # 109902. The Kirby Institute receives funding from the Australian Government Department of Health and Ageing. We gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.

Author Contributions
Conceived and designed the experiments: LN RG LM. Performed the experiments: LN. Analyzed the data: LN. Contributed reagents/materials/analysis tools: RG LM. Wrote the paper: LN RG LM MS BH AT. Additional technical, clinical and/or remote area expertise: MS AT BH JW SB.

References
1. Bowden EJ, Tabrizi SN, Garland SM, Fairley CK (2002) Infections diseases. 6: Sexually transmitted infections: new diagnostic approaches and treatments. Med J Aust 176: 531–537.
2. Oakeshott P, Kelly S, Aghaizae A, Ashworth H, Hay S, et al. (2010) Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 340: c1647.
3. Katz B, Thon S, Blythe M, Arno J, Caine V, et al. (1994) Fertility in adolescent women previously treated for genitourinary chlamydial infection. Adolesc Pediatr Gynecol 7: 147–152.
4. Low N, Egger M, Sterne JA, Harbord RM, Ibrahim F, et al. (2006) Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women’s Cohort Study. Sex Transm Infect 82: 212-218.
5. Bradshaw N, Flood-Shaffer K, Rodriguez E, Johnson-Rubio A, Porter K, et al. (2004) Early outcomes from the West Texas Early Pregnancy and Chlamydia Project: Potential impact on future fertility. Fertility and Sterility 82: S15–S15.
6. Allaire A, Huddleston J, Graves W, Nathan L (1998) Initial and Repeat Screening for Chlamydia trachomatis During Pregnancy. Infectious Diseases in Obstetrics and Gynaecology 6: 116–122.
7. Regan DG, Wilson DP, Hocking JS (2008) Coverage is the key for effective screening of Chlamydia trachomatis in Australia. J Infect Dis 198: 349–358.
8. Hook EW 3rd, Spitters C, Reichart CA, Neumann TM, Quinn TC (1994) Use of cell culture and a rapid diagnostic assay for Chlamydia trachomatis screening. JAMA 272: 862–870.
9. Geiselner WM, Wang C, Morrison SG, Black CM, Bandea CI, et al. (2008) The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis 35: 119–123.
10. Shepard MDS (2004) Chapter 29. Point-of-Care Testing in the Indigenous Rural Environment–The Australian Experience. In: Price C, Hicks J, St John A, editors. Point-of-Care Testing. Second ed. Washington DC: AACCC (American Association of Clinical Chemistry) Press pp. 295–301.
11. Goldenberg SN, Sheweller JA, Oster AG, Koehoorn M (2008) Sexually transmitted infection (STI) testing among young oil and gas workers: the need for innovative, place-based approaches to STI control. Can J Public Health 99: 350–354.
12. Peeling RW (2011) Applying new technologies for diagnosing sexually transmitted infections in resource-poor settings. Sex Transm Infect 87 Suppl 2: i28–30.
13. WHO (2003) Guidelines for the management of sexually transmitted infections. (2002) Evaluation of a rapid point-of-care test for the detection of gonococcal infection among female sex workers in Benin. Sex Transm Infect 82 Suppl 5: v29–32.
14. Watchirs Smith LA, Hillman R, Ward J, Whiley DM, Causer L, et al. (2013) Communicable Disease Control Directorate. (2006) Guidelines for Managing Sexualy Transmitted Infections. Perth: Department of Health, Western Australia.
15. Fagan P (2001) Sexual health service provision in remote Aboriginal and Torres Strait Islander settings in far north Queensland: sexual health symptoms and some outcomes of partner notification. Venerology, 2001;14(2):55–61 14: 55–61.
16. Shephard M (2013) Point-of-Care Testing in Australia: the status, practical advantages, and benefits of community resiliency. Point of Care 12: 41–45.
17. Koerperump EL, Sudaryo MK, de Vlas SJ, Gray RH, Sewankambo NK, et al. (2002) What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic? Int J STD AIDS 13: 91–101.
18. Skov S, Fethers K, Smith K, Baguley S (2003) Sexually Transmitted Infections (STI) in the CARPA Region. In: Steven S, Ewald D, editors. The CARPA Reference Manual (4th Edition).
19. Mayaud P, Mabey D (2004) Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. Sex Transm Infect 80: 174–182.
20. Watchirs Smith LA, Hillman R, Ward J, Whiley DM, Causer L, et al. (2013) Point-of-care tests for the diagnosis of Neisseria gonorrhoeae and chlamydia in urine specimens in the microbiology laboratory: a systematic review of operational and performance characteristics. Sex Transm Infect 89: 320–326.
21. van Dommelen L, van Tiel FH, Ouburg S, Brouwers EE, Terpstra PH, et al. (2016) Alarmingly poor performance in Chlamydia trachomatis point-of-care testing. Sex Transm Infect 86: 355–359.
22. Guy RJ, Natoli L, Ward J, Causer L, Hengel B, et al. (2013) A randomised trial of point-of-care tests for chlamydia and gonorrhoea infections in remote Aboriginal communities: Test, Treat ANd GO- the “TTANGO” trial protocol. BMC Infect Dis 13: 485.
23. Skov S, Fethers K, Smith K, Baguley S (2003) Sexually Transmitted Infections. Perth: Department of Health, Western Australia.
24. van Dommelen L, van Tiel FH, Ouburg S, Brouwers EE, Terpstra PH, et al. (2016) Alarmingly poor performance in Chlamydia trachomatis point-of-care testing. Sex Transm Infect 86: 355–359.
25. Watchirs Smith LA, Hillman R, Ward J, Whiley DM, Causer L, et al. (2013) Communicable Disease Control Directorate. (2006) Guidelines for Managing Sexualy Transmitted Infections. Perth: Department of Health, Western Australia.
26. van Dommelen L, van Tiel FH, Ouburg S, Brouwers EE, Terpstra PH, et al. (2016) Alarmingly poor performance in Chlamydia trachomatis point-of-care testing. Sex Transm Infect 86: 355–359.
27. Guy RJ, Natoli L, Ward J, Causer L, Hengel B, et al. (2013) A randomised trial of point-of-care tests for chlamydia and gonorrhoea infections in remote Aboriginal communities: Test, Treat ANd GO- the “TTANGO” trial protocol. BMC Infect Dis 13: 485.
28. Royal Australian College of General Practitioners (2012) Guidelines for preventive activities in general practice, 8th edn. East Melbourne, Victoria, Australia.
29. STI in Gay Men Action Group (2010) Sexually Transmitted Infection Guidelines For Men Who Have Sex With Men.
30. NACCHO/RACGP (2012) National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people South Melbourne: The RACGP.
31. Guy R, Ward JS, Smith KS, Su JY, Huang RL, et al. (2012) The impact of sexually transmissible infection programs in remote Aboriginal communities in Australia: a systematic review. Sex Health 9: 205–212.
32. McDonagh P, Ryder N, McNulty AM, Freedman E (2009) Neisseria gonorrhoeae infection in urban Sydney women: prevalence and predictors. Sex Health 6: 241–244.
33. Guy R, Garton I, Taylor Thomson D, Silver B, Hengel B, et al. (2011) The 2010 baseline prevalence assessment conducted by the STRIVE trial. Australasian Sexual Health Conference. Canberra, Australia.
34. Lewis D, Newton DC, Guy RJ, Ali H, Chen MY, et al. (2012) The prevalence of Chlamydia trachomatis infection in Australia: a systematic review and meta-analysis. BMC Infect Dis 12: 113.
35. Gibbs L, Kealy M, Willis K, Green J, Welch N, et al. (2007) What have sampling and data collection got to do with good qualitative research? Aust N Z J Public Health 31: 540–544.
36. Pope C, Ziebland S, Mays N (2000) Analysing qualitative data. British Medical Journal 320: 114–116.
37. Peeling RW, Mabey D, Ballard RC (2013) Introducing new diagnostics into STI control programmes: the importance of programme science. Sex Transm Infect 89: 113–119
38. Peeling RW, Holmes KK, Mabey D, Ronald A (2006) Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect 82 Suppl 5: v1–6.
39. Whiley DM, Goire N, Lahra MM, Donovan B, Limnios AE, et al. (2012) The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 67: 2059–2061.
40. Gaydos CA, Van Der Pol B, Jett-Gochen M, Barnes M, Quinn N, et al. (2013) Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 51: 1666–1672.
41. Tabrizi SN, Unemo M, Gofarian D, Twin J, Limnios AE, et al. (2013) Analytical evaluation of GeneXpert CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 51: 1945–1947.
42. Weinstein SA, Stiles BG (2011) A review of the epidemiology, diagnosis and evidence-based management of Mycoplasma genitalium. Sex Health 8: 143–150.
43. Foundation for Innovative New Diagnostics (2013) Malaria Rapid Diagnostic Tests: An implementation Guide. Geneva.
44. London School of Hygiene and Tropical Medicine (2013) The Rapid Syphilis Test Toolkit, A Guide to Planning, Management and Implementation. London: London School of Hygiene and Tropical Medicine.